Allergic Rhinitis Changes the Sinus Microbiome

Completed · Phase 4 · Has a placebo group

Conditions studied: Seasonal Allergic Rhinitis

In brief

The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.

Key facts

Study ID

NCT01852513

Run by

University of Chicago

People needed

39

Starts

2013-01-01

Expected to finish

2014-06-01

Last updated by the study team

2020-10-09

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females between 18 and 55 years of age.
• Two year history of seasonal allergic rhinitis.
• Positive skin test to grass and/or tree antigen.

You may not qualify if…

• Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
• Pregnant or lactating women.
• Subjects treated with systemic steroids during the previous 30 days.
• Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.
• Subjects treated with oral antihistamine/decongestants during the previous seven days.
• Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.
• Subjects treated with immunotherapy and are escalating their dose.
• Subjects on chronic anti-asthma medications.
• Subjects with polyps in the nose or a significantly displaced septum.
• Upper respiratory infection within 14 days prior to study start.

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.